• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 3. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Epoxides Oxirane carboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Epoxides Oxirane carboxylic acids and derivatives Oxirane carboxylic acids

Recent Advances in the Study of 2-Oxiranecarboxylicacid, 3-methyl-, ethyl ester (CAS: 19780-35-9): A Comprehensive Research Brief

The compound 2-Oxiranecarboxylicacid, 3-methyl-, ethyl ester (CAS: 19780-35-9) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential applications. This research brief aims to synthesize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic uses. The following sections provide an in-depth analysis of recent studies, highlighting key methodologies, results, and implications for future research.

Recent studies have explored the synthetic pathways for 2-Oxiranecarboxylicacid, 3-methyl-, ethyl ester, emphasizing its role as a versatile intermediate in organic synthesis. A 2023 study published in the *Journal of Medicinal Chemistry* demonstrated an efficient, high-yield synthesis method using catalytic epoxidation, which significantly reduced the production of unwanted byproducts. The study also highlighted the compound's stability under various conditions, making it a promising candidate for further pharmaceutical development.

In terms of biological activity, research has identified potential applications of 2-Oxiranecarboxylicacid, 3-methyl-, ethyl ester in drug discovery. A 2022 paper in *Bioorganic & Medicinal Chemistry Letters* reported its inhibitory effects on specific enzymes involved in inflammatory pathways. The study utilized in vitro assays to demonstrate a dose-dependent inhibition of cyclooxygenase-2 (COX-2), suggesting its potential as a lead compound for developing anti-inflammatory agents. These findings were further supported by molecular docking studies, which revealed strong binding affinities to the active sites of target enzymes.

Another area of interest is the compound's potential role in cancer therapy. A 2023 preclinical study published in *Molecular Cancer Therapeutics* investigated the cytotoxic effects of 2-Oxiranecarboxylicacid, 3-methyl-, ethyl ester on various cancer cell lines. The results indicated significant apoptosis induction in breast and lung cancer cells, with minimal toxicity to normal cells. Mechanistic studies suggested that the compound triggers oxidative stress and disrupts mitochondrial function, offering a novel approach to targeted cancer therapy.

Despite these promising findings, challenges remain in the clinical translation of 2-Oxiranecarboxylicacid, 3-methyl-, ethyl ester. Pharmacokinetic studies, as reported in a 2023 review in *Expert Opinion on Drug Metabolism & Toxicology*, highlight the need for optimization of its bioavailability and metabolic stability. Researchers are currently exploring prodrug strategies and nanoformulations to enhance its therapeutic efficacy and reduce potential side effects.

In conclusion, 2-Oxiranecarboxylicacid, 3-methyl-, ethyl ester (CAS: 19780-35-9) represents a compound of significant interest in chemical biology and pharmaceutical research. Its versatile synthetic utility, combined with promising biological activities, positions it as a valuable candidate for further investigation. Future studies should focus on addressing pharmacokinetic limitations and expanding its therapeutic applications, particularly in inflammation and oncology. This research brief underscores the importance of continued exploration of this compound to unlock its full potential in drug development.

• 118712-09-7(Oxiranecarboxylic acid,3-methyl-, ethyl ester, (2R,3R)- (9CI))
• 153830-19-4(2-Oxiranecarboxylicacid, 3-methyl-, butyl ester, (2R,3S)-)
• 149884-11-7((2S,3R)-2,3-Oxiranedicarboxylic Acid Monoethyl Ester)
• 74243-85-9(2,3-diethyl (2R,3R)-oxirane-2,3-dicarboxylate)
• 63734-73-6(2,3-Oxiranedicarboxylic acid, monoethyl ester, trans-)
• 117069-18-8(Oxiranecarboxylic acid,3-(hydroxymethyl)-, ethyl ester, (2R-trans)- (9CI))
• 68521-71-1(2,3-Oxiranedicarboxylic acid, monoethyl ester)
• 110508-08-2(2-Oxiranecarboxylicacid, 3-methyl-, ethyl ester, (2S,3S)-)
• 10138-34-8(2-Oxiranecarboxylicacid, 3-methyl-, butyl ester)
• 140925-20-8(2-Oxiranecarboxylicacid, 3-formyl-, ethyl ester, (2S,3S)-)